IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Horizon Pharma plc and Urges Investors to Contact the Firm

LOS ANGELES--()--Lundin Law PC announces it is investigating claims against Horizon Pharma plc (“Horizon Pharma” or the “Company”) (Nasdaq: HZNP) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Horizon Pharma were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation will focus on the February 29, 2016 annual report released by Horizon concerning a subpoena it received in November of 2015. Horizon stated that it had received the subpoena from the U.S. Attorney for the Southern District of New York concerning its paid assistance programs.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com